EA201690321A1 - Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей - Google Patents
Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолейInfo
- Publication number
- EA201690321A1 EA201690321A1 EA201690321A EA201690321A EA201690321A1 EA 201690321 A1 EA201690321 A1 EA 201690321A1 EA 201690321 A EA201690321 A EA 201690321A EA 201690321 A EA201690321 A EA 201690321A EA 201690321 A1 EA201690321 A1 EA 201690321A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- muc1
- treatment
- maitanzinoid
- immunocong
- contract
- Prior art date
Links
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102100034256 Mucin-1 Human genes 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306119 | 2013-08-02 | ||
| PCT/EP2014/066345 WO2015014879A1 (en) | 2013-08-02 | 2014-07-30 | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690321A1 true EA201690321A1 (ru) | 2016-12-30 |
Family
ID=49036539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690321A EA201690321A1 (ru) | 2013-08-02 | 2014-07-30 | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347856A1 (enExample) |
| EP (1) | EP3027218A1 (enExample) |
| JP (1) | JP2016525560A (enExample) |
| KR (1) | KR20160035600A (enExample) |
| CN (1) | CN105592861A (enExample) |
| AU (1) | AU2014298514A1 (enExample) |
| CA (1) | CA2919932A1 (enExample) |
| EA (1) | EA201690321A1 (enExample) |
| IL (1) | IL243843A0 (enExample) |
| MX (1) | MX2016001541A (enExample) |
| TW (1) | TW201605479A (enExample) |
| WO (1) | WO2015014879A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160058884A1 (en) | 2014-09-02 | 2016-03-03 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| GB201506388D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| CN105997942B (zh) * | 2016-06-24 | 2019-01-29 | 浙江大学 | 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用 |
| JP7162011B2 (ja) * | 2017-01-18 | 2022-10-27 | ナノクルーズ・ファーマシューティカル・リミテッド | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 |
| EP3665161B1 (en) * | 2017-08-09 | 2023-09-27 | Helmholtz-Zentrum für Infektionsforschung GmbH | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| JP2022512920A (ja) * | 2018-11-02 | 2022-02-07 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗ｃｄ１６６抗体およびその使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999043347A1 (fr) * | 1998-02-25 | 1999-09-02 | Wakamoto Pharmaceutical Co., Ltd. | Medicaments destines aux troubles de l'epithelium corneen |
| EP1660513B9 (en) * | 2003-07-21 | 2012-04-04 | ImmunoGen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| BRPI0520509A2 (pt) * | 2005-08-22 | 2009-05-12 | Immunogen Inc | anticorpo ou seu fragmento de ligação de epitopo, polinucleotìdeo, célula hospedeira, e método de preparação de um anticorpo ou seu fragmento de ligação de epitopo |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
-
2014
- 2014-07-30 JP JP2016530509A patent/JP2016525560A/ja not_active Abandoned
- 2014-07-30 KR KR1020167004778A patent/KR20160035600A/ko not_active Withdrawn
- 2014-07-30 AU AU2014298514A patent/AU2014298514A1/en not_active Withdrawn
- 2014-07-30 EA EA201690321A patent/EA201690321A1/ru unknown
- 2014-07-30 CN CN201480054398.5A patent/CN105592861A/zh active Pending
- 2014-07-30 US US14/909,671 patent/US20160347856A1/en not_active Abandoned
- 2014-07-30 MX MX2016001541A patent/MX2016001541A/es unknown
- 2014-07-30 EP EP14747592.5A patent/EP3027218A1/en active Pending
- 2014-07-30 WO PCT/EP2014/066345 patent/WO2015014879A1/en not_active Ceased
- 2014-07-30 CA CA2919932A patent/CA2919932A1/en not_active Withdrawn
- 2014-08-01 TW TW103126492A patent/TW201605479A/zh unknown
-
2016
- 2016-01-31 IL IL243843A patent/IL243843A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160347856A1 (en) | 2016-12-01 |
| JP2016525560A (ja) | 2016-08-25 |
| WO2015014879A1 (en) | 2015-02-05 |
| CN105592861A (zh) | 2016-05-18 |
| IL243843A0 (en) | 2016-04-21 |
| KR20160035600A (ko) | 2016-03-31 |
| CA2919932A1 (en) | 2015-02-05 |
| MX2016001541A (es) | 2016-08-18 |
| WO2015014879A9 (en) | 2015-11-19 |
| TW201605479A (zh) | 2016-02-16 |
| AU2014298514A1 (en) | 2016-03-10 |
| EP3027218A1 (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| JOP20210073A1 (ar) | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها | |
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| UA115517C2 (uk) | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| UA110370C2 (en) | Conjugates of amatoxin with improved linkages | |
| BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| PH12015500392A1 (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| PH12016500214A1 (en) | Antibody drug conjugates (adc) that bind to cd37 proteins | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA202190102A1 (ru) | Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака | |
| WO2017062615A3 (en) | Combination therapy for the treatment of cancer | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof |